qv3wv6ef

Property	Value
?:abstract	PURPOSE Coronavirus-2019 (COVID-19) mortality is higher in patients with cancer than in the general population, yet the cancer-associated risk factors for COVID-19 adverse outcomes are not fully characterized. PATIENTS AND METHODS We reviewed clinical characteristics and outcomes from patients with cancer and concurrent COVID-19 at Memorial Sloan Kettering Cancer Center until March 31, 2020 (n = 309), and observed clinical end points until April 13, 2020. We hypothesized that cytotoxic chemotherapy administered within 35 days of a COVID-19 diagnosis is associated with an increased hazard ratio (HR) of severe or critical COVID-19. In secondary analyses, we estimated associations between specific clinical and laboratory variables and the incidence of a severe or critical COVID-19 event. RESULTS Cytotoxic chemotherapy administration was not significantly associated with a severe or critical COVID-19 event (HR, 1.10; 95% CI, 0.73 to 1.60). Hematologic malignancy was associated with increased COVID-19 severity (HR, 1.90; 95% CI, 1.30 to 2.80). Patients with lung cancer also demonstrated higher rates of severe or critical COVID-19 events (HR, 2.0; 95% CI, 1.20 to 3.30). Lymphopenia at COVID-19 diagnosis was associated with higher rates of severe or critical illness (HR, 2.10; 95% CI, 1.50 to 3.10). Patients with baseline neutropenia 14-90 days before COVID-19 diagnosis had worse outcomes (HR, 4.20; 95% CI, 1.70 to 11.00). Findings from these analyses remained consistent in a multivariable model and in multiple sensitivity analyses. The rate of adverse events was lower in a time-matched population of patients with cancer without COVID-19. CONCLUSION Recent cytotoxic chemotherapy treatment was not associated with adverse COVID-19 outcomes. Patients with active hematologic or lung malignancies, peri-COVID-19 lymphopenia, or baseline neutropenia had worse COVID-19 outcomes. Interactions among antineoplastic therapy, cancer type, and COVID-19 are complex and warrant further investigation.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/qv3wv6ef_hasAnnotation_C0006826> <https://research.tib.eu/covid-19/entity/qv3wv6ef_hasAnnotation_C0020517> <https://research.tib.eu/covid-19/entity/qv3wv6ef_hasAnnotation_C0027627> <https://research.tib.eu/covid-19/entity/qv3wv6ef_hasAnnotation_C0068526> <https://research.tib.eu/covid-19/entity/qv3wv6ef_hasAnnotation_C0242379> <https://research.tib.eu/covid-19/entity/qv3wv6ef_hasAnnotation_C0376545> <https://research.tib.eu/covid-19/entity/qv3wv6ef_hasAnnotation_C0877248>
?:creator	<https://research.tib.eu/covid-19/entity/Jee%2C_Justin%3B_Foote%2C_Michael_B%3B_Lumish%2C_Melissa%3B_Stonestrom%2C_Aaron_J%3B_Wills%2C_Beatriz%3B_Narendra%2C_Varun%3B_Avutu%2C_Viswatej%3B_Murciano-Goroff%2C_Yonina_R%3B_Chan%2C_Jason_E%3B_Derkach%2C_Andriy%3B_Philip%2C_John%3B_Belenkaya%2C_Rimma%3B_Kerpelev%2C_Marina%3B_Maloy%2C_Molly%3B_Watson%2C_Adam%3B_Fong%2C_Chris%3B_Janjigian%2C_Yelena%3B_Diaz%2C_Luis_A%3B_Bolton%2C_Kelly_L%3B_Pessin%2C_Melissa_S>
?:doi	<https://research.tib.eu/covid-19/entity/10.1200/jco.20.01307>
?:doi	10.1200/jco.20.01307
?:journal	Journal_of_clinical_oncology_:_official_journal_of_the_American_Society_of_Clinical_Oncology
?:license	unk
?:pmid	<https://research.tib.eu/covid-19/entity/32795225.0>
?:pmid	32795225.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/qv3wv6ef_HAS_C0206750_COEXISTS_WITH_C0376545>
?:source	Medline
?:title	Chemotherapy and COVID-19 Outcomes in Patients With Cancer.
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-08-14

Property

Value

?:abstract

PURPOSE Coronavirus-2019 (COVID-19) mortality is higher in patients with cancer than in the general population, yet the cancer-associated risk factors for COVID-19 adverse outcomes are not fully characterized. PATIENTS AND METHODS We reviewed clinical characteristics and outcomes from patients with cancer and concurrent COVID-19 at Memorial Sloan Kettering Cancer Center until March 31, 2020 (n = 309), and observed clinical end points until April 13, 2020. We hypothesized that cytotoxic chemotherapy administered within 35 days of a COVID-19 diagnosis is associated with an increased hazard ratio (HR) of severe or critical COVID-19. In secondary analyses, we estimated associations between specific clinical and laboratory variables and the incidence of a severe or critical COVID-19 event. RESULTS Cytotoxic chemotherapy administration was not significantly associated with a severe or critical COVID-19 event (HR, 1.10; 95% CI, 0.73 to 1.60). Hematologic malignancy was associated with increased COVID-19 severity (HR, 1.90; 95% CI, 1.30 to 2.80). Patients with lung cancer also demonstrated higher rates of severe or critical COVID-19 events (HR, 2.0; 95% CI, 1.20 to 3.30). Lymphopenia at COVID-19 diagnosis was associated with higher rates of severe or critical illness (HR, 2.10; 95% CI, 1.50 to 3.10). Patients with baseline neutropenia 14-90 days before COVID-19 diagnosis had worse outcomes (HR, 4.20; 95% CI, 1.70 to 11.00). Findings from these analyses remained consistent in a multivariable model and in multiple sensitivity analyses. The rate of adverse events was lower in a time-matched population of patients with cancer without COVID-19. CONCLUSION Recent cytotoxic chemotherapy treatment was not associated with adverse COVID-19 outcomes. Patients with active hematologic or lung malignancies, peri-COVID-19 lymphopenia, or baseline neutropenia had worse COVID-19 outcomes. Interactions among antineoplastic therapy, cancer type, and COVID-19 are complex and warrant further investigation.

is ?:annotates of